Effect of Xuefu Zhuyu capsule on platelet function in patients with clopidogrel resistance after PCI
Li Hui
Zhang Yijiao
Guo Huimin
An Jingxia
Liu Jinjun
Sun Yingying
Abstract：Objective To explore the effect of Xuefu Zhuyu capsule on platelet aggregation and activation in patients with clopidogrel resistance(CR)after percutaneous coronary intervention(PCI).Methods A total of 82 patients with cor-onary heart disease who underwent PCI treatment in Handan Central Hospital from January 2022 to March 2023 were select-ed and divided into a control group(aspirin+clopidogrel)and a study group(aspirin+clopidogrel+Xuefu Zhuyu capsule)by double-blind random number table method,with 41 in each group.The platelet aggregation rate,liver and kidney function indicators(aspartate aminotransferase(AST),blood urea nitrogen(BUN),alanine aminotransferase(ALT),serum creatinine(Scr)),platelet activation indicators(CD62P,P-selectin,GPⅡb/Ⅲa),hemorheological indicators(whole blood viscosity,plasma viscosity,fibrinogen),and the incidence of adverse cardiovascular events were recorded and compared between the two groups.Results Following the treatment,both the study group and the control group exhibited reduced platelet aggregation rates((34.12±10.09)％,(42.23±12.71)％),which were significantly lower than their pre-treatment levels((61.58±9.23)％,(61.77±8.92)％).Additionally,the study group demonstrated a lower rate than the control group,and the difference was statistically significant(t=-3.200,P<0.05).After treatment,the AST,BUN,ALT,and Scr levels in both groups were(25.44±4.81)U·L-1,(30.23±5.76)U·L-1,(4.95±1.53)mmol·L-1,(5.87±1.21)mmol·L-1,(27.84±6.47)U·L-1,(33.62±7.53)U·L-1,(103.57±8.32)μmol·L-1,(122.19±8.26)μmol·L-1.These values were higher than those recorded before treatment((23.79±3.68)U·L-1,(23.86±3.57)U·L-1,(3.34±1.85)mmol·L-1,(3.29±1.64)mmol·L-1,(24.37±4.58)U·L-1,(23.98±4.82)U·L-1,(97.85±7.13)μmol·L-1,(97.90±6.94)μmol·L-1),but the degree of elevation in the study group was lower than that in the control group,and the differences were statistically significant(t=4.087,-3.020,3.728,10.169,all P<0.05).Regarding platelet selector,P-selectin,platelet glycoprotein Ⅱb/Ⅲa,whole blood viscos-ity,plasma viscosity,and fibrinogen levels,post-treatment values for the study group((4.19±1.03)％,(11.65±3.27)％,(31.62±6.73)％,(58.27±7.54)％,(45.54±8.21)％,(65.81±8.96)％,(5.53±0.21)mPa·s-1,(5.97±0.23)mPa·s-1,(1.62±0.15)mPa·s-1,(2.11±0.17)mPa·s-1,(3.25±0.14)g·L-1,(3.52±0.23)g·L-1)were notably lower than their pre-treatment levels((16.72±2.36)％,(17.05±2.17)％,(62.31±4.15)％,(62.77±4.36)％,(69.85±7.71)％,(70.36±7.82)％,(6.24±0.51)mPa·s-1,(6.26±0.53)mPa·s-1,(2.43±0.33)mPa·s-1,(2.45±0.27)mPa·s-1,(3.96±0.51)g·L-1,(3.95±0.47)g·L-1).The study group consistently showed lower values,and the differences were statistically signif-icant(t=-13.933,-16.884,-10.680,-9.046,-13.839,-6.421,all P<0.05).In terms of adverse event incidence,the study group re-ported a rate of 14.63％,which was significantly lower than the control group's 34.15％,and the difference was statistically significant(χ2=4.232,P<0.05).Conclusion For patients with CR after PCI,Xuefu Zhuyu capsule can effectively reduce the platelet aggre-gation rate,effectively improve the platelet activation index,and reduce the damage of aspirin or clopidogrel on the liver and kidney function of patients,decrease the blood viscosity level,and reduce the probability of adverse cardiovascular events.
Keywords：Xuefu Zhuyu capsulePCIClopidogrel resistancePlatelet aggregationPlatelet activation
Publication Date：2025-08-25
Online Publishing Date：2025-09-01(First online date of this platform, not the publication date of the document)
Pages：5( 904-908 )